Ozempic and Wegovy Linked to Rare Risk of Sudden Vision Loss

Drugs like Ozempic and Wegovy, which are widely used for managing diabetes and supporting weight loss, have been associated with a small increase in the risk of a rare eye condition that can cause sudden and sometimes permanent loss of vision.

What the Research Shows

A recent study by researchers at Rutgers found that people taking these drugs, which belong to a class called GLP-1 receptor agonists, may face a slightly elevated chance of developing this unusual eye complication. However, it is important to emphasize that this risk is very low overall.

Understanding the Evidence

The findings come from population-level research observing patients using these medications. While a link was observed, this does not prove that Ozempic or Wegovy cause the vision loss directly, only that there is an association that needs further study.

Limitations and Uncertainties

Because the condition is rare and the studies are observational, it is unclear what mechanisms might contribute to the risk or how significant it is for individual patients. There is no data yet showing whether the increased risk affects all users equally or if specific groups might be more vulnerable.

The studies do not confirm whether stopping the drug reduces risk or impacts vision outcomes.

What This Means for Patients and Providers

Given millions of people use GLP-1 agonists like Ozempic and Wegovy for diabetes and weight management, awareness of this potential risk is important. Patients experiencing sudden vision changes should seek medical attention promptly.

Healthcare professionals may consider monitoring eye health in patients prescribed these medications, but experts emphasize that the benefits of these drugs for controlling blood sugar and aiding weight loss remain substantial.

Overall, this finding serves as a reminder of the need for ongoing surveillance of new and existing medications to balance benefits and rare but serious harms.

Source: ScienceDaily Medical